CORRECTING AND REPLACING: Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

by Barry101 | May 16, 2018 | Press Release

ORLANDO, Fla., May 16, 2018 — In a release issued earlier today by Hemispherx Biopharma, Inc. (NYSE American:HEB) with the same headline, the net loss from operations was incorrect in the fourth paragraph. It should say $0.07 per share, not $0.70 per share....

Hemispherx Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update

by Barry101 | May 16, 2018 | Press Release

ORLANDO, Fla., May 16, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB), an advanced specialty pharmaceutical company engaged in the treatment of serious and debilitating disorders through the development of its immunology products Ampligen® and...

Hemispherx to Present at the 4th Annual Immuno-Oncology: BD&L and Investment Forum

by Barry101 | May 14, 2018 | Press Release

ORLANDO, Fla., May 14, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 4th Annual Immuno-Oncology: BD&L and Investment Forum on Friday, June 1 at 3:40PM CDT (the time may be subject to changes...

Hemispherx to Present at the 8th Annual LD Micro Invitational

by Barry101 | May 10, 2018 | Press Release

ORLANDO, Fla., May 10, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) announced today that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 11:00 AM PT (the time may be subject to changes depending on the conference...

Hemispherx Provides an Update to Stockholders Highlighting Cancer Focus and $10 Million Booked Since Start of Year Will Support Increased Production of Ampligen for Immuno-Oncology Clinical Trials

by Barry101 | May 2, 2018 | Press Release

ORLANDO, Fla., May 02, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) would like to share a letter with its stockholders today, highlighting 2017 results, recent achievements, and outlining plans to take the company forward with emphasis on the...

Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market

by Barry101 | Apr 20, 2018 | Press Release

ORLANDO, Fla., April 20, 2018 — Hemispherx Biopharma, Inc. (NYSE American:HEB) (“Hemispherx” or the “Company”), a research and development and emerging commercial growth company focused on unmet medical needs in immunology, with a special...